Investment Rating - The report maintains a "Buy" rating for the company [2][8] Core Insights - The company has launched a new product, "Injectable Recombinant Type III Humanized Collagen Gel," utilizing the innovative HiveCOL "honeycomb" collagen tissue network technology, which fills an international gap in the market [5][8] - The product features a dual-core functional area design that is 100% humanized, enhancing its immediate shaping and tissue regeneration capabilities [8] - The company is expected to see significant revenue growth, with projected net profits of 1.148 billion, 1.539 billion, and 1.934 billion yuan for 2025, 2026, and 2027 respectively, reflecting a growth rate of 56.8%, 34.1%, and 25.6% [7][8] Financial Data and Profit Forecast - Total revenue is projected to grow from 1,443 million yuan in 2024 to 3,952 million yuan in 2027, with a compound annual growth rate of approximately 35.0% [7][10] - The gross margin is expected to remain high at around 90% across the forecast period, indicating strong profitability [7][8] - The company's return on equity (ROE) is projected to be 45.8%, 41.6%, and 37.4% for 2025, 2026, and 2027 respectively, showcasing efficient use of equity [7][8]

Core Viewpoint - New Oxygen (SY) reported a strong financial performance for Q1 2025, with revenue reaching 297 million yuan, driven by a significant growth in its light medical beauty chain business, which achieved 98.88 million yuan in revenue, marking a 551% year-on-year increase, indicating a successful strategic transformation [1][4]. Group 1: Financial Performance - In Q1 2025, New Oxygen's revenue was 297 million yuan, with the light medical beauty chain business contributing 98.88 million yuan, a 551% increase year-on-year, achieving a record high for a single quarter [1]. - The chain business has shown continuous growth for six consecutive quarters, with over 92,900 projects redeemed in the quarter, a 989% increase year-on-year, and over 45,500 paid users, an 874% increase [4]. Group 2: Business Strategy and Growth - The company is focusing on its transformation strategy, emphasizing the development of the light medical beauty chain business and investing in vertical integration and business diversification to strengthen its competitive position in the evolving medical beauty sector [1][8]. - New Oxygen has established its first light medical beauty chain store in May 2023, rapidly expanding its presence and becoming a leading player in the industry [1]. Group 3: Customer Satisfaction and Service Model - New Oxygen's service model emphasizes transparency, high quality, and cost-effectiveness, leading to a user satisfaction score of 4.98 out of 5 in Q1 [5]. - The company has expanded its professional doctor team with a 10% acceptance rate, ensuring consistent quality in medical delivery through systematic training and digital management [6]. Group 4: Product and Platform Development - The company has developed a robust upstream product ecosystem, with over 1,500 service institutions and a 14% year-on-year increase in the shipment of its hyaluronic acid brand, exceeding 27,900 units in Q1 2025 [8]. - New Oxygen is transitioning its platform to a "premium mall" model to enhance user experience and conversion rates, with a total transaction value (GMV) of 303 million yuan in Q1 2025 [8].

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [2] Core Insights - The retail industry is experiencing a significant shift with the 618 e-commerce promotion, characterized by extended activity periods and simplified consumer engagement strategies [27][28] - Domestic beauty brands are showing strong performance, with notable sales figures during the 618 promotion, indicating a trend of rising domestic products [5][32] Summary by Sections Retail Market Review - The retail industry index rose by 1.72% during the week of May 12 to May 16, outperforming the Shanghai Composite Index by 0.96 percentage points [7][16] - The internet e-commerce sector saw the highest growth, with a weekly increase of 5.81%, while the brand cosmetics sector led the year-to-date performance with a 20.30% increase [19][22] 618 Promotion Insights - The 618 e-commerce promotion has begun, with platforms like Taobao, Douyin, and JD extending their promotional periods and simplifying discount mechanisms to enhance consumer experience [27][28] - Sales performance during the promotion has been strong, with Li Jiaqi's live stream achieving a GMV of 25-35 billion yuan on the first day, showcasing the rising dominance of domestic beauty brands [5][32] Investment Recommendations - Focus on high-quality companies in the emotional consumption theme, particularly in sectors like gold jewelry, offline retail, cosmetics, and medical aesthetics [8][35] - Recommended companies include Lao Pu Gold, Chao Hong Ji, Mao Ge Ping, Peiliya, Juzi Biology, and Shangmei Shares, which are expected to benefit from current market trends [38]

创业板指跌幅扩大至1%，上证指数跌0.26%，深证成指跌0.83%。机器人、消费电子、医美、白酒等方 向跌幅居前，沪深京三市下跌个股近3600只。 ...

Investment Rating - The report maintains a "Positive" investment rating for the beauty industry [3] Core Insights - The beauty industry is experiencing stable growth, with a notable performance in the collagen restructuring segment [1][5] - The overall revenue growth for the cosmetics sector has shown slight improvement, with a year-on-year increase of 3.1% in Q1 2025, recovering from previous negative growth [12][19] - The average revenue growth for the cosmetics industry is projected to be 8% in 2024, followed by a decline to -5% in Q1 2025, indicating a trend of increasing differentiation among brands [19] Summary by Sections Cosmetics - The cosmetics industry has shown a steady growth rate, with Q1 2025 marking a recovery from three consecutive quarters of negative growth [12] - Online sales channels, particularly Tmall and Douyin, have seen significant growth, with a combined increase of 17% in Q1 2025 [12] - The average revenue growth for brands has been more resilient compared to upstream and downstream segments, with mid-sized brands like Marubi and Runben achieving good growth despite a generally weak market [19] Medical Beauty - The medical beauty sector has seen a convergence in revenue, while the collagen restructuring segment continues to maintain high growth rates [1][5] Revenue and Profitability - The average revenue growth for the cosmetics industry has been declining, with a notable differentiation in performance among brands [19] - The average gross margin for the brand segment has slightly increased, attributed to improved business structure and price control measures [20] Product Innovation - Brands are focusing on upgrading main product lines and expanding functional categories, particularly in sun protection and whitening, with increased competition expected [25] - New product launches include significant upgrades in major brands like Proya and Bethany, focusing on whitening and sun protection [24][25] Expenses and Profit Margins - The average sales expense ratio for brands has increased, reflecting heightened competition and rising platform costs [26] - The gross profit margin has generally decreased across the industry, although leading brands like Proya have managed to improve their margins through effective cost management [26][35] R&D and Management Expenses - There is a trend of increasing R&D investment among leading brands, with a shift towards foundational research [45] - Management expense ratios have shown a divergence, with leading companies optimizing their expenses while others have seen increases due to business adjustments [45]

E-commerce and New Retail - Douyin E-commerce has provided over 8 billion yuan in subsidies to merchants in the first four months of this year, including over 3 billion yuan in January and February, 2 billion yuan in March, and 2.5 billion yuan in April, reflecting its strategy to enhance merchant retention and loyalty amid fierce competition [1] - Alibaba's Q4 FY2025 report shows revenue of 236.45 billion yuan, a 7% year-on-year increase, with cloud revenue growing by 18% driven by strong AI demand, marking the seventh consecutive quarter of triple-digit growth in AI-related product revenue [2] - Tencent has established an e-commerce product department to explore new transaction models within WeChat, aiming to leverage its vast user base to enhance its e-commerce capabilities and address its lag behind competitors like Alibaba and JD [3] - JD Group reported Q1 2025 revenue of 301.1 billion yuan, a 15.8% year-on-year increase, with active user growth exceeding 20% for six consecutive quarters, driven by investments in supply chain and logistics [4] - The "618" shopping festival has commenced, with JD and Taobao Tmall launching promotional activities that integrate low prices, services, and entertainment to attract and retain customers [6] Life Services - New Oxygen reported a 6.6% year-on-year decline in Q1 2025 revenue to 297 million yuan, with net losses widening to 331 million yuan, although its light medical beauty chain business saw a significant revenue increase of 551.4% to 98.88 million yuan [7] Logistics and Supply Chain - JD Logistics reported Q1 revenue of 46.97 billion yuan, an 11.5% year-on-year increase, with a profit of 751.5 million yuan, reflecting strong service quality and operational efficiency [10] Innovation and Investment - Self-variable Robotics has completed a series A financing round of several hundred million yuan, led by Meituan, to accelerate the development of its intelligent robotics and models, enhancing Meituan's automation capabilities in delivery and retail [12]

Group 1 - The core viewpoint of the articles highlights the significant growth potential in the consumer healthcare sector in China, driven by increasing health awareness among consumers and the emergence of innovative business models [1][3] - The number of registered medical beauty companies in China has surged, with over 16,000 existing companies and more than 60% established in the last three years, indicating a trend of traditional medical companies diversifying into consumer healthcare [2][3] - Companies like Kelun Pharmaceutical are pivoting towards the health sector, with their medical beauty business starting to generate revenue despite varying contributions across different firms [6][7] Group 2 - The medical beauty sector is becoming a new growth point for traditional medical enterprises, with many companies forming new entities or acquiring existing ones to enter this market [2][3] - The integration of artificial intelligence (AI) in consumer healthcare is expected to create new growth opportunities, enhancing personalized services and improving operational efficiency [3][4] - The financial performance of companies in the medical beauty sector is showing promising trends, with some reporting significant revenue growth, such as a 66.4% increase in medical beauty revenue for a specific company [6][8] Group 3 - The demand for regenerative medicine is rapidly increasing, with a notable rise in interest for stem cell therapies, although the current application in medical beauty does not fully meet the technical standards of regenerative medicine [5][6] - Regulatory frameworks are evolving to support the commercialization of cell therapies, with recent guidelines issued by the National Medical Products Administration to clarify the development and clinical trial processes [8]

Summary of Conference Call Records Industry Overview - The new consumption sector shows significant differentiation, with the personal care industry growing faster than medical beauty and cosmetics. Brand iteration is accelerating, leading to widening performance gaps among companies such as Mao Ge Ping, Shangmei, and Juzi Biological, which are experiencing rapid growth, while Shanghai Jahwa and Huaxi Biological are seeing slower growth [1][4]. Key Insights and Arguments - **Beauty Sector Valuation**: The beauty sector still has room for valuation improvement, with PEG values referencing 2019 levels. Recommended companies include Jingbo Biological, Juzi Biological, and Dengkang Oral Care, along with Japanese brands Perfect Diary and Shangmei Life [1][5]. - **Food and Beverage Sector**: Focus is on food additives and snacks, with Baiming Chuangyuan expected to experience rapid growth from 2024 to 2026 due to capacity release and new product approvals. The current valuation is around 20 times. The konjac products are driving explosive growth in the snack sector, with attention on Yanjinpuzi and Wehaomei [1][6]. - **High School Education Reform**: The reform in the high school education system is favorable for private high schools, with Tianli International Holdings being undervalued at a PEG of about 0.3 and an annual growth rate of approximately 35%. Other companies like Xueda Education and Kevin Education are also worth monitoring [1][7][8]. - **Domestic Brands Growth**: Domestic brands are rapidly rising, while overseas brands, particularly from Japan and South Korea, are declining. The American brand group has collapsed in the domestic market, with only L'Oréal managing to sustain itself, but its momentum is expected to diminish next year [2]. Additional Important Insights - **AI in Consumption**: The AI-enhanced consumption sector is thriving, with AI glasses, AI e-commerce, AI education, and AI toys being the four core directions. Recommended companies include Kangnait Optical, with attention on Focus Technology, Xiaogoods City, and Haizhu Wang [3][11]. - **Traditional Retail Recommendations**: In traditional retail, focus on high dividend-yielding stocks. Companies like Chongqing Department Store, Bubugao, and Dashang Co. are highlighted for their stability and dividend performance [12]. - **Pet Industry Trends**: The pet industry is showing strong sales trends, particularly during the 618 shopping festival, with domestic brands rapidly gaining market share. Brands like Guibao Pet and Zhongchong Co. are maintaining strong growth momentum [16][17]. - **Home Appliance Sector**: The home appliance sector is expected to see improved revenue due to promotional activities and national subsidy policies, despite increased price competition. Companies like Midea and Haier are actively engaging in price wars to boost sales [18][19][20]. Conclusion The new consumption sector is characterized by rapid growth in personal care and food sectors, with significant opportunities in AI applications and domestic brands. The education reform and pet industry trends also present promising investment avenues. The home appliance sector faces challenges but shows potential for recovery through strategic pricing and export opportunities.

商贸零售 2025 年 05 月 18 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -29% -14% 0% 14% 29% 43% 2024-05 2024-09 2025-01 商贸零售 沪深300 相关研究报告 《关注零售行业中期投资策略：深挖 情 绪 消 费 景 气 赛 道 — 行 业 周 报 》 -2025.5.11 《悦享生活，深挖情绪消费景气赛道 —2025 年零售行业中期投资策略》 -2025.5.7 《零售企业经营持续承压，关注高景 气优质公司—行业周报》-2025.5.5 618 大促拉开帷幕，关注国货美妆表现 ——行业周报 | 黄泽鹏（分析师） | 陈思（联系人） | | --- | --- | | huangzepeng@kysec.cn | chensi@kysec.cn | | 证书编号：S0790519110001 | 证书编号：S0790124070031 | chensi@kysec.cn 证书编号：S0790124070031 投资主线三（化妆品）：关注具备差异化且能力持续迭代的优质国货美妆品牌， 重点推荐毛戈平、珀莱雅、上美股份、巨子生物、润本股份、丸美生物等 ...

Core Viewpoint - The article discusses the rebuttal by Huaxi Biological regarding the "outdated hyaluronic acid theory," claiming it is a narrative constructed by "restless capital" to divert attention from the necessary evolution of China's industry [1][4]. Group 1: Industry Context - Huaxi Biological argues that the rise of the "outdated hyaluronic acid theory" is a result of misleading narratives that have emerged in recent years, portraying hyaluronic acid as inferior to other substances [3][4]. - The company highlights that since 2022, the capital market has shifted its focus to the concept of recombinant collagen, which has been promoted through misleading comparative studies against the hyaluronic acid industry [3][4]. Group 2: Company Performance - Huaxi Biological has experienced a significant decline in net profit and stock price, with its market value dropping from over 140 billion yuan in 2021 to just 24.3 billion yuan currently [7]. - In contrast, competitors like Juzhi Biological, which went public in Hong Kong in 2022, have seen both their performance and stock price rise, with a current market value of 90.9 billion HKD [8]. - Another competitor, Jinbo Biological, listed on the Beijing Stock Exchange, has also seen its stock price double in recent months, reaching a market value of 42.5 billion yuan [9].